Streetbeat News

Products Services

IMMP

Immutep has reported promising efficacy and tolerability from its INSIGHT-003 trial at the ESMO Congress 2023. The trial involved efti plus anti-PD-1 therapy and doublet chemotherapy as first-line therapy in metastatic non-squamous non-small cell lung cancer. The trial showed a 71.4% Overall Response Rate, 90.5% Disease Control Rate, 10.1-month median Progression Free Survival, and median Overall Survival that has not been reached.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 12:09 pm

XMTR

Xometry, Inc. (NASDAQ:XMTR) has integrated its Teamspace collaboration tool into its AI-powered marketplace. The cloud-based project management software provides real-time project visibility and collaboration on large, mission-critical projects. Teamspace was built with direct input from high-volume customers and has been tested with major organizations. It simplifies quote and order management and drives data-driven decision-making.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 12:08 pm

RNAZ

TransCode Therapeutics, Inc. (NASDAQ:RNAZ) announced preliminary results from its Phase 0 clinical trial of its lead therapeutic candidate, TTX-MC138, for treating metastatic cancer. The data showed that TTX-MC138 was successfully delivered to metastatic lesions and had pharmacokinetic behavior consistent with non-clinical IND-enabling studies. The patient tolerated the dosing with no reported adverse reactions. The trial is not intended to demonstrate a therapeutic effect but to inform dose selection and frequency for further clinical development.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 12:07 pm

RYZB

The FDA has selected RayzeBio to participate in its inaugural CDRP program, aimed at expediting commercial manufacturing readiness for RYZ101 in GEP-NETs.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 12:05 pm

UNH

UnitedHealthcare, a division of UnitedHealth Group (UNH), announced it will offer individual and family plans on the Health Insurance Marketplace in 26 states for 2024. The plans will include benefits such as $0 unlimited primary and virtual urgent care, prescriptions as low as $5, dental and vision coverage, and up to $100 in reward incentives. The company is expanding its ACA Marketplace offerings into four new states: New Jersey, New Mexico, South Carolina, and Wisconsin.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 12:04 pm

MAIA

MAIA has announced preliminary efficacy data from its ongoing THIO-101 Phase 2 trial. The company reported a 100% preliminary Disease Control Rate (DCR) in second-line patients and 88% in third-line patients. These patients are considered highly difficult to treat as they have already progressed through previous lines of treatment.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 12:04 pm

INM

InMed Pharmaceuticals has announced that its drug INM-901 has shown unique pharmacological effects in Alzheimer's disease in preclinical proof-of-concept studies.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 11:51 am

VVOS

Vivos Therapeutics has signed a nationwide distribution agreement with Lincare. This deal will allow Vivos' products to be distributed across the country, potentially increasing the company's market reach and sales.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 11:32 am

NEO

NeoGenomics has announced the commercial availability of two new tests. The company has not provided details about the tests or their potential impact on the company's revenues.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 11:09 am

AZN

The US Food and Drug Administration (FDA) has accepted AstraZeneca's supplemental biologics license application for self-administration of FLUMIST QUADRIVALENT (Influenza Vaccine Live, Intranasal).

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 11:07 am